Stryker Corporation Reports 10.3% Revenue Growth in Q3 2025

Stryker Corporation reported a strong financial performance for the third quarter of 2025, with net sales reaching $6.057 billion, a 10.3% increase compared to $5.494 billion in the same period last year. For the first nine months of 2025, the company achieved net sales of $17.945 billion, up 11.1% from $16.159 billion in 2024. The gross profit for the quarter was $3.852 billion, translating to a gross margin of 63.6%, while net earnings were $859 million, or $2.22 per diluted share, reflecting a slight increase from $834 million, or $2.16 per diluted share, in the prior year.

The company experienced notable changes in its operating expenses, which rose to $2.717 billion in the third quarter from $2.432 billion in 2024. This increase was primarily driven by higher selling, general, and administrative expenses, which accounted for $2.045 billion, up from $1.894 billion. Research and development expenses also increased to $410 million from $377 million. Despite these rising costs, Stryker's operating income for the quarter was $1.135 billion, slightly higher than $1.085 billion in the previous year, resulting in an operating income margin of 18.7%.

Strategically, Stryker completed the acquisition of Inari Medical in February 2025 for approximately $4.810 billion, which is expected to enhance its Vascular business within the MedSurg and Neurotechnology segment. The acquisition aligns with Stryker's goal of expanding its market presence and diversifying its product offerings. Additionally, the company restructured its Spine business in late 2024, which included renaming segments and reclassifying certain product lines to better align with its internal reporting structure.

Operationally, Stryker reported an increase in customer engagement, with significant growth in product shipments across all MedSurg and Neurotechnology businesses. The company’s total assets increased to $47.057 billion as of September 30, 2025, up from $42.971 billion at the end of 2024. The company also maintained a strong liquidity position, with cash and cash equivalents totaling $3.256 billion. Stryker's employee headcount remained stable, with 382.4 million shares of common stock outstanding as of the end of the quarter.

Looking ahead, Stryker anticipates continued growth driven by its strategic acquisitions and product innovations. The company expects to navigate potential challenges posed by macroeconomic factors, including tariffs and inflation, while leveraging its strong market position to enhance shareholder value. The effective tax rate for the third quarter was 16.5%, down from 20.0% in the previous year, contributing to the overall positive outlook for the remainder of 2025.